01:30 AM EDT, 08/03/2026 (MT Newswires) -- Swedish Orphan Biovitrum (SOBI.ST), or Sobi's, Chief Executive Officer Guido Oelkers will leave the company at the end of January 2027 to pursue an external opportunity. The Swedish pharmaceuticals company will launch the search process for Oelkers' successor immediately, according to a Monday release.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.